Bempegaldesleukin

Modify Date: 2024-07-17 08:00:35

Bempegaldesleukin structure	Common Name	Bempegaldesleukin
	CAS Number	1939126-74-5	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Bempegaldesleukin

Bempegaldesleukin (NKTR-214), a PEGylated interleukin-2 (IL-2), is an immunostimulatory IL-2 prodrug acting as a CD122-preferential IL-2 pathway agonist. Bempegaldesleukin can stimulate an antitumor immune response[1].

Name	Bempegaldesleukin

Description	Bempegaldesleukin (NKTR-214), a PEGylated interleukin-2 (IL-2), is an immunostimulatory IL-2 prodrug acting as a CD122-preferential IL-2 pathway agonist. Bempegaldesleukin can stimulate an antitumor immune response[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Immunology/Inflammation >> Interleukin Related Research Areas >> Inflammation/Immunology
In Vitro	Bempegaldesleukin 是一种 IL-2 前体药物，经过改造可提供受控、持续和优先的 IL-2 通路信号，目的是刺激抗肿瘤免疫反应，同时最大限度地降低毒性[1]。
In Vivo	Bempegaldesleukin (0.8 mg/kg; i.v. for 7 d) + NKTR-262 以 CD8+ T 细胞依赖性方式显着改善两种肿瘤模型 (CT26 和 EMT6) 的存活率[2]< /sup>。
References	[1]. Tannir NM, et, al. Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. J Immunother Cancer. 2022 Apr;10(4):e004419. [2]. Rolig AS, et, al. Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT. J Immunother Cancer. 2022 Apr;10(4):e004218.

No Any Chemical & Physical Properties

Bempegaldesleukin

Use of Bempegaldesleukin

Names

Bempegaldesleukin Biological Activity

Chemical & Physical Properties